BioDelivery Sciences International, Inc. (BDSI) announced it has entered into a worldwide licensing agreement with Arcion Therapeutics. Under the agreement, BioDelivery Sciences will develop and commercialize topical clonidine gel for the treatment of painful diabetic neuropathy and potentially other indications.
BioDelivery Sciences will make an upfront payment of $2 million to Arcion in the form of unregistered shares of common stock. Additional financial terms include a milestone payment to Arcion of $2.5 million in unregistered shares of BioDelivery stock upon acceptance by the FDA of a NDA for topical clonidine gel and a cash payment to Arcion of between $17.5 and $35 million upon NDA approval, depending on certain regulatory and commercial considerations. The agreement also includes sales milestones and low single-digit royalties on net worldwide sales.
BioDelivery Sciences estimates annual peak sales potential for topical clonidine gel in excess of $300 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.